As we have seen previously (see this link), among men with Gleason 9 or 10 disease, brachy boost therapy (BBT) provided better oncological outcomes compared to either radical prostatectomy (RP) alone or external beam radiation therapy (EBRT) alone. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachy boost, surgery, Treatment, very high-risk | 8 Comments »
We have long been bedeviled by questions about some of the short- and the long-term side effects and complications of androgen deprivation therapy (ADT) in the treatment of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, Alzheimer's, androgen, dementia, deprivation, failure, heart, side effect | 2 Comments »
According to a recently reported study in the journal European Urology, men who received first-line surgery or radiation therapy for non-metastatic prostate cancer were significantly more likely to have taken an antidepressant 5 years later than comparable men who didn’t get such treatment. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: antidepressant, depression, monitoring, radiartion, surgery, surveillance, therapy | 7 Comments »
We have probably all heard terms like “liquid biopsy” and “genetic screening” and “cell-free” DNA analysis over the past few years. These are all terms related to the use of genetic and genomic information to “personalize” cancer diagnosis and its management. And they are potentially a huge big deal. But, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: analysis, cancer, detection, DNA, Management, monitoring, risk | 4 Comments »
We have recently learned that Medicare will be covering the costs of the Oncotype DX AR-V7 Nucleus Detect™ test for patients with metastatic, castration-resistant prostate cancer (mCRPC) as of December 10, 2018. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: AR-V7, Genomic Health, Oncotype, test | 4 Comments »
Bayer has announced a new clinical trial of the latest entry in the race for radiopharmaceuticals to treat prostate cancer, joining 177Lu PSMA-617, 225Ac PSMA-617, and 131I MIP-1095. They are trying thorium-227 attached to a PSMA antibody. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: alpha-emitter, radiopharmaceutical, thorium-227, trial | Leave a comment »
The above headline comes from information released yesterday by the American Society for Clinical Oncology (ASCO). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: alternative, care, delusion, knowledge | 18 Comments »
